Merck Receives FDA Approval for Keytruda as Adjuvant Therapy in High-Risk Cervical Cancer

Merck today announced that the FDA has approved Keytruda (pembrolizumab) as adjuvant therapy for patients with high-risk early-stage cervical cancer following surgery. The approval was based on the Phase 3 KEYNOTE-A18 trial, which demonstrated a statistically significant improvement in disease-free survival for pembrolizumab plus chemoradiotherapy versus chemoradiotherapy alone. This approval represents the first immunotherapy approved in the adjuvant setting for cervical cancer and provides a new treatment option for patients at high risk of recurrence after surgery.